New treatment targeting cancer cells and their supportive environment in Non-Hodgkin Lymphoma.
Official title: Biomarker Rich Clinical Trial of an Innovative Antibody Antagonist of TNFR2 in Non-Hodgkin Lymphoma Featuring Cutaneous T Cell Lymphoma (CTCL).
Funded at Boston Immune Technologies and Therapeutics, INC. · NIH-10911718 · Data updated 2026-11-12
This study is testing a new treatment called BITR2101 that targets a specific part of cancer cells to help stop the growth of Non-Hodgkin Lymphoma, especially for those with Cutaneous T Cell Lymphoma, and it may be used on its own or with other therapies to improve patient outcomes.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Boston Immune Technologies and Therapeutics, INC. NIH-funded |
| Lab location | 1 site (Winchester, United States) |
| Project start | September 1, 2021 |
| Project end | June 30, 2026 |
| Funding year | 2024 |
| Award (this year) | $1,565,481 |
| NIH project number | 2R44CA265510-04 |
| Project ID | NIH-10911718 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with Non-Hodgkin Lymphoma, especially those with Cutaneous T Cell Lymphoma.
✕Less likely to help
Patients with other types of cancer or those who do not express TNFR2 may not benefit from this research.
What this research studies
This research focuses on developing a novel antibody, BITR2101, that targets TNFR2, a receptor found in cancer cells and their surrounding supportive cells. By inhibiting TNFR2 signaling, the treatment aims to disrupt the cancer's ability to grow and resist therapy. Patients will be evaluated for their response to this innovative therapy, which may be used alone or in combination with other treatments. The study seeks to improve outcomes for patients with Non-Hodgkin Lymphoma, particularly those with Cutaneous T Cell Lymphoma.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for Non-Hodgkin Lymphoma, improving survival rates and quality of life for patients.
How similar studies have gone: Other research has shown promise in targeting similar pathways in cancer treatment, indicating potential for success with this novel approach.
Where this research is happening
-
Boston Immune Technologies and Therapeutics, INC.
Winchester, United States Active
Researchers
- Principal investigator: Brooks, David G — Boston Immune Technologies and Therapeutics, INC.
- Study coordinator: Brooks, David G
Related research
Other NIH-funded projects on the same topics.
-
New antibody treatment for Non-Hodgkin Lymphoma and a type of skin lymphoma
This project is testing a new antibody treatment, called BITR2101, for people with certain types of cancer, including Non-Hodgkin Lymphoma and Cutaneous T Cell Lymphoma.
-
Novel combination therapy for non-Hodgkin lymphoma in people and dogs
A new treatment combo using an oncolytic virus and other therapies is being tested to help people with hard-to-treat non-Hodgkin lymphoma, with studies also involving dogs to better understand responses.
-
Combination therapy approach for non-Hodgkin lymphoma (NHL)
A Mayo Clinic team is testing a new combination treatment for non-Hodgkin lymphoma to improve responses in patients and in dogs with similar disease.
-
Multi-antigen T cell therapy for relapsed NHL
A patient-derived T cell therapy called MT-601 targets six tumor-associated antigens to help treat relapsed non-Hodgkin lymphoma after other therapies may have failed.
-
IL-15 and skin-homing CTCL: a targeted approach to curb skin lesions
This grant studies how the inflammatory signal IL-15 drives CTCL T cells to settle in the skin and how blocking this pathway might help patients with this skin-limited leukemia.
-
Staphylococcus aureus and CTCL: How skin bacteria may drive a blood cancer
A doctor-scientist team is studying how certain strains of Staphylococcus aureus on the skin might influence the development and progression of cutaneous T-cell lymphoma (CTCL) in patients.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.